nach oben

memo - Magazine of European Medical Oncology

Tipp

Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

verfasst von: Patrick Reimann, Thomas Winder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Summary

In this short review we aim to summarize the highlights in gastric, gastroesophageal junction and oesophageal cancer in 2021. We will discuss practice changing studies and potential guideline changes based on these trials, with focus on the latest developments regarding checkpoint inhibitors.

Vorheriger Artikel Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

Nächster Artikel Multiple myeloma with central nervous system relapse: a case report

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. CrossRef

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86. CrossRef

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203. CrossRef

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. CrossRef

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. CrossRef

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD‑1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. CrossRef

Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed death-ligand 1‑expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392–402. CrossRef

Leone AG, Petrelli F, Ghidini A, Raimondi A, Smyth EC, Pietrantonio F. Efficacy and activity of PD‑1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score. ESMO Open. 2022;7(1):100380. CrossRef

Shen L, Lu Z, Wang J, Shu Y, Kong L, Yang L, et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study. Ann Oncol. 2021;32(5):1283–346.

10.

Xu R, Wang F, Cui C, Yao J, Zhang Y, Wang G, et al. JUPITER-06: a randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ann Oncol. 2021;32(5):1040–75.

11.

Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, et al. PD-L1 immunohistochemistry comparison of 22C3 and 28‑8 assays for gastric cancer. J Gastrointest Oncol. 2021;12(6):2696–705. CrossRef

12.

Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26(24):6453–63. CrossRef

13.

Cancer Genome A, Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. CrossRef

14.

Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute; Brown University, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75. CrossRef

Titel: Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021
verfasst von: Patrick Reimann
Thomas Winder
Publikationsdatum: 09.05.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00809-6

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

Summary

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far

Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better

Neoadjuvant treatment for solid tumors—the earlier, the better

CAR T cells in multiple myeloma: Where we stand and where we might be going

Molecular profiling in lung cancer

Publisher Correction: Brain metastases: new systemic treatment approaches